Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.